Sanchi Vohra
Research Subjects
Sanchi Vohra has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kanika Bhardwaj
Centre for Sight Eye Institute
4 shared publications - Tulika Chauhan
Centre for Sight Eye Institute
4 shared publications Bharat R. Thoumungkan
Centre for Sight Eye Institute
1 shared publication- Garvita Dabas
Centre for Sight Eye Institute
1 shared publication - Krishna Teja Boggarapu
Centre for Sight Eye Hospital
1 shared publication - Parul Ichhpujani
Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India
1 shared publication
Latest Publications
- 1 January 2024
- Published by Springer Nature
- p. 115-121
The Masters of Mimicry: Atypical Viral Presentation
- 1 January 2024
- Published by Springer Nature
- p. 115-121
The Masters of Mimicry: Atypical Viral Presentation
- 1 January 2024
- Published by Springer Nature
- p. 103-113
Advanced Keratoconus with Hydrops: Light at the End of the Tunnel
- 1 January 2024
- Published by Springer Nature
- p. 103-113
Advanced Keratoconus with Hydrops: Light at the End of the Tunnel
- 1 January 2024
- Published by Springer Nature
- p. 83-88
Moving Backward Is Not Retreating: Management of Pigment Dispersion Syndrome (PDS) Post Photorefractive Keratectomy (PRK)
- 1 January 2024
- Published by Springer Nature
- p. 83-88
Moving Backward Is Not Retreating: Management of Pigment Dispersion Syndrome (PDS) Post Photorefractive Keratectomy (PRK)
- 1 January 2024
- Published by Springer Nature
- p. 89-93
Chemical Keratopathy: Caught on the Hop
- Open Access
- 1 April 2020
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 50 (2) , 75-81
Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost
The use of benzalkonium chloride (BAC)-preserved medications is associated with ocular surface disease (OSD) that can negatively affect quality of life (QoL) in glaucoma patients. This study aimed to compare QoL and correlate it with OSD in glaucoma patients receiving BAC-preserved and BAC-free travoprost. A total of 110 subjects were divided into 3 groups: 40 primary open-angle glaucoma (POAG) patients using BAC-preserved travoprost, 40 POAG patients using BAC-free travoprost, and 30 age-matched controls. All patients were assessed using a single interviewer-administered format of the Ocular Surface Disease index (OSDI) and Glaucoma Quality of Life-15 (GQL-15) questionnaires. Mean GQL-15 score in the BAC group was significantly higher than in the BAC-free group (24.71±7.42 vs. 17.58±3.06; p0.05). There was a strong positive correlation between OSDI scores and GQL-15 scores in all the groups (r values: BAC: 0.63, BAC-free: 0.23, controls: 0.29), with higher OSDI scores (severe OSD) associated with higher GQL-15 scores (worse QoL). Cronbach's alpha was 0.84 for GQL-15 and 0.75 for OSDI. BAC-preserved travoprost leads to higher OSDI scores, which correlate strongly with poor QoL scores as compared to BAC-free travoprost. The use of BAC-free formulations should be encouraged to reduce the onset or worsening of OSD and impaired QoL in glaucoma patients.
- 1 April 2020
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 50 (2) , 75-81
Open AccessCorrelation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost
The use of benzalkonium chloride (BAC)-preserved medications is associated with ocular surface disease (OSD) that can negatively affect quality of life (QoL) in glaucoma patients. This study aimed to compare QoL and correlate it with OSD in glaucoma patients receiving BAC-preserved and BAC-free travoprost. A total of 110 subjects were divided into 3 groups: 40 primary open-angle glaucoma (POAG) patients using BAC-preserved travoprost, 40 POAG patients using BAC-free travoprost, and 30 age-matched controls. All patients were assessed using a single interviewer-administered format of the Ocular Surface Disease index (OSDI) and Glaucoma Quality of Life-15 (GQL-15) questionnaires. Mean GQL-15 score in the BAC group was significantly higher than in the BAC-free group (24.71±7.42 vs. 17.58±3.06; p0.05). There was a strong positive correlation between OSDI scores and GQL-15 scores in all the groups (r values: BAC: 0.63, BAC-free: 0.23, controls: 0.29), with higher OSDI scores (severe OSD) associated with higher GQL-15 scores (worse QoL). Cronbach's alpha was 0.84 for GQL-15 and 0.75 for OSDI. BAC-preserved travoprost leads to higher OSDI scores, which correlate strongly with poor QoL scores as compared to BAC-free travoprost. The use of BAC-free formulations should be encouraged to reduce the onset or worsening of OSD and impaired QoL in glaucoma patients.